Showing 9 posts of 9 posts found.


NHS England to fund Hemlibra for patients with severe haemophilia

August 21, 2019
Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma

NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …


Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors

March 14, 2019
Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma

Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …


Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients

December 4, 2018
Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma

In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …


FDA expands indication of Roche’s Hemlibra in haemophilia

October 5, 2018
Medical Communications, Sales and Marketing Hemlibra, Roche, haemophilia, pharma

The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the …


Roche’s Hemlibra stakes claim to be haemophilia market leader

May 21, 2018
Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …


Five deaths linked to Roche’s haemophilia drug Hemlibra

March 28, 2018
Research and Development Genentech, Hemlibra, Roche, haemophilia, pharma

Roche has been rocked by the revelation that there have been five patient deaths linked to the use of its …

Europe approves first therapy for haemophilia A with inhibitors in over 20 years

March 1, 2018
Research and Development Europe, European Commission, Hemlibra, Roche, haemophilia, pharma

Roche has revealed that its bispecific factor IXa- and factor X-directed antibody Hemlibra (emicizumab) has been approved by the European …

Roche’s haemophillia A treatment gets nod but with black box warning

November 17, 2017
Medical Communications, Sales and Marketing Hemlibra, Roche, biotech, drugs, pharma, pharmaceutical

Roche needs its pipeline to pick up quick successes, with its big earners are looking at precipitous patent cliffs, and, …

Latest content